MedPath

Efficacy and safety of olanzapine suppositories in terminally ill patients with delirium or nausea and vomiting.

Not Applicable
Conditions
delirium, nausea and vomiting
Registration Number
JPRN-UMIN000022172
Lead Sponsor
Shonan Central Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

We exclude children and patients with taking orally.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Responses to olanzapine therapy are evaluated based on clinical assessments by physicians. Information about the side effects is extracted from the electronic medical records of each patient.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath